Anzeige
Mehr »
Login
Samstag, 02.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Technischer Ausbruch: Diese Kupferaktie ist in den letzten 52 Wochen um 300 % gestiegen! Der Durchbruch läuft!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A143YN | ISIN: GB00BYX3WZ24 | Ticker-Symbol: 5HU
Frankfurt
01.11.24
21:49 Uhr
0,010 Euro
0,000
0,00 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
HEMOGENYX PHARMACEUTICALS PLC Chart 1 Jahr
5-Tage-Chart
HEMOGENYX PHARMACEUTICALS PLC 5-Tage-Chart

Aktuelle News zur HEMOGENYX PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiIN BRIEF: Hemogenyx to launch myeloid leukemia treatment phase 1 trial-
MiHemogenyx Pharmaceuticals PLC Announces Schedule for Phase I Clinical Trial Opening87Hemogenyx Pharmaceuticals Announces Schedule for Opening First Clinical Site for Phase I Trial of HEMO-CAR-T (HG-CT-1) LONDON, UK / ACCESSWIRE / October 30, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO)...
► Artikel lesen
MiHemogenyx Pharma Plc - Schedule for Phase I Clinical Trial Opening1
02.10.Hemogenyx shares boosted by partner investment6
02.10.Hemogenyx Pharmaceuticals PLC Announces Strategic Investment from Prevail Partners, LLC284Prevail Partners, LLC to invest again in Hemogenyx PharmaceuticalsPrevail InfoWorks, Inc. to act as Clinical Research Organization (CRO) for upcoming Phase I pediatric clinical study LONDON, UNITED...
► Artikel lesen
02.10.Hemogenyx Pharma Plc - Strategic Investment from Prevail Partners, LLC1
27.09.Hemogenyx Pharmaceuticals loss narrows amid reduced expenses1
27.09.Hemogenyx Pharmaceuticals PLC Announces Half-year Report133LONDON, UNITED KINGDOM / ACCESSWIRE / September 27, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing therapies designed to transform blood disease treatment, whose...
► Artikel lesen
27.09.Hemogenyx Pharma Plc - Half-year Report2
09.09.Hemogenyx Pharmaceuticals PLC - FLT3 Assay Ready for Phase I Trials at MD Anderson140LONDON, UNITED KINGDOM / ACCESSWIRE / September 9, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), a clinical-stage biopharmaceutical group focused on developing treatments for cancers and viral diseases...
► Artikel lesen
09.09.Hemogenyx Pharma Plc - FLT3 Assay Ready for Phase I Trials at MD Anderson1
02.09.Hemogenyx Pharmaceuticals PLC Announces CDX Development Update245CDX Development Update LONDON, UNITED KINGDOM / ACCESSWIRE / September 2, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO)("Hemogenyx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical...
► Artikel lesen
02.09.Hemogenyx Pharma Plc - CDX Development Update1
28.08.Hemogenyx Pharmaceuticals PLC Announces Presentation at CBD S&T Conference154LONDON, UNITED KINGDOM / ACCESSWIRE / August 28, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the clinical-stage biopharmaceutical group developing treatments for cancers and viral diseases, is...
► Artikel lesen
28.08.Hemogenyx Pharma Plc - Presentation at CBD S&T Conference1
29.07.Hemogenyx Pharmaceuticals PLC Announces Macrophage-Directed Therapies Summit Presentation264Presentation at Macrophage-Directed Therapies Summit LONDON, UNITED KINGDOM / ACCESSWIRE / July 29, 2024 / Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company")(LSE:HEMO), the...
► Artikel lesen
29.07.Hemogenyx Pharma Plc - Macrophage-Directed Therapies Summit Presentation-
27.06.Hemogenyx Pharmaceuticals PLC Announces Result of Annual General Meeting239LONDON, UNITED KINGDOM / ACCESSWIRE / June 27, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that, at the Annual General Meeting ("AGM") held earlier today, all resolutions...
► Artikel lesen
27.06.Hemogenyx Pharma Plc - Result of Annual General Meeting1
17.06.IN BRIEF: Hemogenyx Pharmaceuticals updates on leukemia treatment1
Seite:  Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1